Due to our earlier observation23, 24 that epidermal growth factor receptor (EGFR) and hepatocyte growth factor receptor (MET) inhibitors reduce the activation of the MAPK and PI3K/AKT signalling pathways, and thus significantly decrease the viability and invasion of CM, we decided to test whether these drugs would also be effective in MM. This evidence concerns the gene EGFR and Miyoshi myopathy.